Search results for Lifastuzumab
Lifastuzumab Biosimilar – Anti-SLC34A2 mAb – Research Grade, ProteoGenix, PX-TA1334
Description of Lifastuzumab Biosimilar - Anti-SLC34A2 mAb - Research Grade General information on Anti-SLC34A2[Homo sapiens] (Lifastuzumab) Monoclonal Antibody Lifastuzumab is investigated for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer.
Host
Reactivity
Applications
Conjugation
Lifastuzumab, Abbexa, abx831293
Lifastuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting SLC34A2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Research Grade Lifastuzumab (HF574016), abinScience, HF574016
Host
Humanized
Reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Conjugation
Please provide the required information below so that we can quickly source your products.